Trials / Completed
CompletedNCT06635317
Efficacy of Aspirin in Preventing Venous Thromboembolism
Efficacy of Arpirin in Preventing Venous Thromboembolism in Total Knee and Hip Replacement
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Efficacy of aspirin and enoxaparin in preventing venous tromboembolism was compared after total knee or hip arthroplasty.
Detailed description
Background: Venous thromboembolism (VTE) remains a significant risk following joint replacements, despite advancements in prevention strategies. Aspirin-based therapies have gained popularity due to their perceived safety, ease of administration, and supportive evidence.This study aimed to compare the efficacy of aspirin and enoxaparin in preventing VTE after total knee or hip arthroplasty. Methods: Sixty patients undergoing primary total knee or hip arthroplasty were randomized to receive either aspirin or enoxaparin. The primary outcome was symptomatic VTE within 90 days. Patients were followed up for Doppler ultrasound evaluations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | 100 mg/day orally for 25 days |
| DRUG | enoxaparin | 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m². |
Timeline
- Start date
- 2022-04-24
- Primary completion
- 2022-10-24
- Completion
- 2023-02-28
- First posted
- 2024-10-10
- Last updated
- 2024-10-10
Locations
1 site across 1 country: Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06635317. Inclusion in this directory is not an endorsement.